Covance to Open Second Current Good Manufacturing Practice (cGMP) Pharmacy in U.S.

Covance is the only CRO to offer cGMP manufacturing in a U.S. Phase I Clinical Research Unit BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 21, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Covance Drug Development will open a cGMP-compliant pharmacy at

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that for the period of September 12, 2015 to March 11, 2016 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 10, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Thursday, September 17, 2015 at 1:30 PM (ET) .

LabCorp Expands Partnership with Perinatal Quality Foundation to Educate Patients and Healthcare Providers about Noninvasive Prenatal Testing

PQF and LabCorp Build On Established Collaboration that Promotes Appropriate Use of Innovative Technologies in Clinical Care BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 3, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today an expansion of its long-standing

Covance Announces Pioneering Agreement with Leading Pharmaceutical Company for Worldwide Portfolio-Level Clinical Trial Monitoring

Xcellerate® Monitoring sets new standard for risk-based monitoring of clinical trials PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that Covance Drug Development (Covance) has received a multi-year award from

LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel

VistaSeq strategically focuses on actionable genetic mutations to identify patients with increased risk of many commonly diagnosed cancers BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide

LabCorp Announces New Covance Leadership

Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Deborah Keller will succeed Joseph Herring as Chief Executive Officer of Covance Drug

Laboratory Corporation of America® Holdings Announces Record 2015 Second Quarter Results and Raises 2015 Adjusted EPS Guidance

Q2 Net revenue of $2.2 billion , up 46% over last year Q2 Diluted EPS of $1.64 ; Q2 Adjusted EPS of $2.09 , up 14% over last year Q2 Free Cash Flow of $328 million , up 106% over last year 2015 Adjusted EPS guidance raised to $7.75 - $8.00 from $7.55 - $7.90 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul.

Covance Opens Fit-for-Purpose Dallas Clinical Research Unit

LabCorp patient service center to be co-located in new facility to serve local patients and enhance volunteer recruitment DALLAS --(BUSINESS WIRE)--Jul. 23, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Covance Drug Development has relocated its

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.